CPIG
AKBA icon

Chicago Partners Investment Group’s Akebia Therapeutics AKBA Stock Holding History

Chicago Partners Investment Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
+19,400
New +$23.1K ﹤0.01% 1535

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
PWP
Parkwoods Wealth Partners Syracuse, New York $622M AUM 24.36% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Chicago Partners Investment Group's AKBA Position: Q2 2026 in Review

Chicago Partners Investment Group opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 19,400 shares worth $23.7K. The stake represents ﹤0.01% of the portfolio and ranks #1535 among its holdings.

35 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Chicago Partners Investment Group held 19,400 shares of Akebia Therapeutics worth $23.7K as of Q2 2026.
  • Akebia Therapeutics was a new Chicago Partners Investment Group position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1535 holding.
  • 35 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.